Arlington Partners’s Fulgent Genetics FLGT Stock Holding History

Arlington Partners’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-200	Closed	-$11K	–	398
2022 Q2	$11K	Hold	200	–	–	﹤0.01%	370
2022 Q1	$12K	Buy	+200	New	+$13.2K	﹤0.01%	367

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arlington Partners's FLGT Position: Q3 2022 in Review

Arlington Partners sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 200 shares — an estimated $11K sold.

Arlington Partners first reported a position in FLGT in Q1 2022 and held it in 2 quarters. The position peaked at $12K in Q1 2022. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

Arlington Partners reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
Arlington Partners sold 200 Fulgent Genetics shares in Q3 2022, an estimated $11K.
Arlington Partners first reported a position in Fulgent Genetics in Q1 2022 and held it in 2 quarters.
Arlington Partners's Fulgent Genetics position peaked at $12K in Q1 2022.
235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Arlington Partners's 13F filing for Q3 2022, filed 28 Oct 2022.